Patent intelligence · US
US 11879003
Methods for increasing T-cell function
Methods for increasing T-cell function
Patent details — US 11879003
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 23, 2024
- Expiration
- Jan 18, 2044
- Applicant
- Kyverna Therapeutics, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/4242
Quick answer
US 11879003 (Methods for increasing T-cell function) is held by Kyverna Therapeutics, Inc.. Status: granted. Granted Jan 23, 2024. Expires Jan 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kyverna Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/4242, A61K40/4254, A61K48/005
More from Kyverna Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11879003?
US 11879003 (Methods for increasing T-cell function) is held by Kyverna Therapeutics, Inc.. Status: granted. Granted Jan 23, 2024. Expires Jan 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11879003?
Kyverna Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 11879003 expire?
Our index shows an expiration date of Jan 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.